The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area
Abstract Introduction Basal cell carcinoma (BCC) is the most common skin malignancy in Caucasians. Globally, about 20% of BCCs involve the periocular region. The treatment of periocular BCC may be very challenging because of its proximity to the intracranial structures. Thus, early diagnosis and ear...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-07-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-023-00985-1 |
| _version_ | 1827859786131046400 |
|---|---|
| author | Alessia Villani Gabriella Fabbrocini Giuseppe Micali Luigi Fornaro Luca Potestio Massimiliano Scalvenzi |
| author_facet | Alessia Villani Gabriella Fabbrocini Giuseppe Micali Luigi Fornaro Luca Potestio Massimiliano Scalvenzi |
| author_sort | Alessia Villani |
| collection | DOAJ |
| description | Abstract Introduction Basal cell carcinoma (BCC) is the most common skin malignancy in Caucasians. Globally, about 20% of BCCs involve the periocular region. The treatment of periocular BCC may be very challenging because of its proximity to the intracranial structures. Thus, early diagnosis and early treatment is mandatory. Recently, the introduction of Hedgehog pathway inhibitor therapy revolutionized the management of unresectable BCCs. The aim of our study was to evaluate the outcome of sonidegib treatment in patients affected by periocular locally advanced (la) BCC at our skin cancer center. Methods A 3-year retrospective study was carried out enrolling patients with periocular laBCC treated with sonidegib. Therapeutic response was defined as complete remission (CR) in case of complete regression of the tumor, partial remission (PR) in case of tumor regression not achieving complete remission, and stable disease (SD). Results A total 16 patients (11 men and 5 women; medium age 71.6 ± 11.5 years) with periocular laBCCs undergoing treatment with 200 mg/day of sonidegib were included in our study. Patients included in the study were treated for at least 6 months for a median duration of 9 months. Overall, CR was reported in 9/16 (56.2%) patients, PR was reported in 4/16 patients (25%), and tumor remained stable in 3 patients (18.8%). No cases of disease progression were collected. Fourteen out of 16 patients experienced multiple adverse events (AEs): dysgeusia was reported in 12 (75%) patients, muscle spasms in 13 (81%) patients, and 7 (43.7%) patients presented with alopecia. However, all of the AEs were mild and none required treatment discontinuation. Conclusion To the best of our knowledge, this is the first study investigating the effectiveness and safety of sonidegib in the management of BCC localized at the periocular region. Even if limited, our study suggests this drug as a valuable and safe option in periocular BCC management. |
| first_indexed | 2024-03-12T13:13:31Z |
| format | Article |
| id | doaj.art-8682d49207bc47678999290829570c31 |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-03-12T13:13:31Z |
| publishDate | 2023-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-8682d49207bc47678999290829570c312023-08-27T11:09:59ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722023-07-011392121212610.1007/s13555-023-00985-1The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular AreaAlessia Villani0Gabriella Fabbrocini1Giuseppe Micali2Luigi Fornaro3Luca Potestio4Massimiliano Scalvenzi5Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico IIDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico IIDermatology Clinic, University of CataniaDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico IIDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico IIDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico IIAbstract Introduction Basal cell carcinoma (BCC) is the most common skin malignancy in Caucasians. Globally, about 20% of BCCs involve the periocular region. The treatment of periocular BCC may be very challenging because of its proximity to the intracranial structures. Thus, early diagnosis and early treatment is mandatory. Recently, the introduction of Hedgehog pathway inhibitor therapy revolutionized the management of unresectable BCCs. The aim of our study was to evaluate the outcome of sonidegib treatment in patients affected by periocular locally advanced (la) BCC at our skin cancer center. Methods A 3-year retrospective study was carried out enrolling patients with periocular laBCC treated with sonidegib. Therapeutic response was defined as complete remission (CR) in case of complete regression of the tumor, partial remission (PR) in case of tumor regression not achieving complete remission, and stable disease (SD). Results A total 16 patients (11 men and 5 women; medium age 71.6 ± 11.5 years) with periocular laBCCs undergoing treatment with 200 mg/day of sonidegib were included in our study. Patients included in the study were treated for at least 6 months for a median duration of 9 months. Overall, CR was reported in 9/16 (56.2%) patients, PR was reported in 4/16 patients (25%), and tumor remained stable in 3 patients (18.8%). No cases of disease progression were collected. Fourteen out of 16 patients experienced multiple adverse events (AEs): dysgeusia was reported in 12 (75%) patients, muscle spasms in 13 (81%) patients, and 7 (43.7%) patients presented with alopecia. However, all of the AEs were mild and none required treatment discontinuation. Conclusion To the best of our knowledge, this is the first study investigating the effectiveness and safety of sonidegib in the management of BCC localized at the periocular region. Even if limited, our study suggests this drug as a valuable and safe option in periocular BCC management.https://doi.org/10.1007/s13555-023-00985-1SonidegibHedgehog inhibitorBasal cell carcinomaVismodegibSkin cancer |
| spellingShingle | Alessia Villani Gabriella Fabbrocini Giuseppe Micali Luigi Fornaro Luca Potestio Massimiliano Scalvenzi The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area Dermatology and Therapy Sonidegib Hedgehog inhibitor Basal cell carcinoma Vismodegib Skin cancer |
| title | The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area |
| title_full | The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area |
| title_fullStr | The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area |
| title_full_unstemmed | The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area |
| title_short | The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area |
| title_sort | efficacy of sonidegib in treating locally advanced basal cell carcinoma involving the periocular area |
| topic | Sonidegib Hedgehog inhibitor Basal cell carcinoma Vismodegib Skin cancer |
| url | https://doi.org/10.1007/s13555-023-00985-1 |
| work_keys_str_mv | AT alessiavillani theefficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT gabriellafabbrocini theefficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT giuseppemicali theefficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT luigifornaro theefficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT lucapotestio theefficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT massimilianoscalvenzi theefficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT alessiavillani efficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT gabriellafabbrocini efficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT giuseppemicali efficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT luigifornaro efficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT lucapotestio efficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea AT massimilianoscalvenzi efficacyofsonidegibintreatinglocallyadvancedbasalcellcarcinomainvolvingtheperioculararea |